Phytochemical, Cytotoxicity, and Antimycobacterial Activity Evaluation of Extracts and Compounds from the Stem Bark of Albizia coriaria Welw ex. Oliver

Samuel Baker Obakiro,1,2,3 Ambrose Kiprop,2,3 Isaac K’owino,3,4 Moses Andima,5 Richard Oriko Owor,5 Robi Chacha,6 and Elizabeth Kigondu7

1Department of Pharmacology and Therapeutics, Faculty of Health Sciences, Busitema University, P.O. Box 1460, Mbale, Uganda
2Department of Chemistry and Biochemistry, School of Sciences and Aerospace Studies, Moi University, P.O. Box 3900-30100, Eldoret, Kenya
3Africa Centre of Excellence II in Phytochemicals, Textile and Renewable Energy (ACE II PTRE), Moi University, P.O. Box 3900-30100, Eldoret, Kenya
4Department of Pure and Applied Chemistry, Faculty of Science, Masinde-Muliro University of Science and Technology, P.O. Box 190-50100, Kakamega, Kenya
5Department of Chemistry, Faculty of Science Education, Busitema University, P.O Box 236, Tororo, Uganda
6Centre of Respiratory Disease Research, Kenya Medical Research Institute, P.O. Box 54840-00200, Nairobi, Kenya
7Centre of Traditional Medicine and Drug Research, Kenya Medical Research Institute, P.O. Box 54840-00200, Nairobi, Kenya

Correspondence should be addressed to Samuel Baker Obakiro; sobakiro@gmail.com

Received 14 November 2021; Revised 4 January 2022; Accepted 5 January 2022; Published 22 January 2022

Background. Albizia coriaria Welw ex. Oliver (Fabaceae) is one of the plants used by herbalists in the East Africa community to prepare herbal remedies for the management of symptoms of TB. Despite its widespread use, the antimycobacterial activity of this plant was uninvestigated and there was contradicting information regarding its cytotoxicity. Methods. Cytotoxicity (MTT), antimycobacterial activity (MABA), and phytochemical screening were conducted on crude extracts (hexane, chloroform, acetone, and methanol) of the stem bark of A. coriaria. Gas chromatography-mass spectrometry (GC-MS) followed by Fourier transform infrared (FTIR) spectroscopy was carried out on the acetone and methanol extracts. The binding affinities and descriptors of pharmacokinetics and toxicity of the identified compounds were predicted using computational modelling software. Results. The cytotoxic concentrations of all extracts were greater than 1000 μg/mL. The minimum inhibitory concentration of both the acetone and methanol extracts was 1250.0 ± 0.0 μg/mL against M. smegmatis, whereas that against M. tuberculosis was 937.0 ± 442.0 μg/mL and 2500.0 ± 0.0 μg/mL, respectively. Hexane and chloroform extracts were not active against both strains. Alkaloids, triterpenes, flavonoids, tannins, and saponins were the predominant phytochemicals present. GC-MS analysis revealed twenty-eight and nineteen compounds in acetone and methanol extracts, respectively. Among these was hydroquinone, which was previously reported to possess antimycobacterial activity. Seven compounds identified through GC-MS analysis had better binding affinities for the mycobacterial ATPase and polyketide synthase-13 than isoniazid and rifampicin. These compounds also showed variable but promising pharmacokinetic properties with minimum toxicity. Conclusion. There are phytochemicals in A. coriaria stem bark with potential antimycobacterial activity and acceptable cytotoxicity, which can be further explored and optimized for the development of novel antitubercular drugs.
1. Introduction

Tuberculosis (TB) is among the top ten diseases with high mortality and morbidity worldwide [1]. TB is caused by *Mycobacterium tuberculosis* (*M. tuberculosis*), a highly infectious bacillus that mainly affects the pulmonary system but also other extrapulmonary organs [2]. In 2020, 1.5 million deaths of TB were recorded worldwide, of which Africa and South-East Asia contributed 85% [1]. Uganda, Kenya, and the United Republic of Tanzania are among the thirty most burdened countries by TB worldwide [1]. Over the past decades, tremendous success has been achieved in the management of TB. However, the rapid emergence and spread of multidrug-resistant *M. tuberculosis* strains have reduced the efficacy of the first-line antitubercular drugs resulting in treatment failures [3]. Additionally, the current antitubercular drugs are administered for a long time (6–9 months), potentially interact with antiretroviral drugs, and are also associated with several side effects that reduce adherence to treatment [4, 5]. Hence, there is a need to identify new efficacious and safe antitubercular drugs with shorter periods of administration.

Medicinal plants continue to be a leading source of novel molecules for the development of new therapies against various ailments [6]. *Albizia coriaria* Welw ex. Oliver (Fabaceae) is one of the widely used plants in the preparation of herbal remedies for the management of symptoms of TB in the East Africa community [7–10]. Some of the common names of *A. coriaria* include worm-bark, cherry-blossom, false-thorn, worm-cure Albizia tree, (English), Ober, Omogi (Luo), Olerai (Luhya) in Kenya, Itek, Bata (Lango), Ober, Ayekayek (Acholi), Musita (Lusoga), Mugavu (Luganda), Etek, Elekwa (Ateso), Musiisa (Lukiga and Lutoro), and Murongo (Lunyankore) in Uganda [11]. *A. coriaria* is a deciduous tree that grows up to 35 m tall with fewer spreading branches. The stem bark is rough, grey-black, and raggedly scaling. The young branches are hairy with alternate leaves, bipinnately compound with 3–7 pairs of pinnae, oblong to elliptic, wide, and rounded. The flowers are whitish-red, scented with hanging red stamen bearing half-spherical anther heads. The fruit is a brown pod with a pointed apex [12]. *A. coriaria* is less geographically distributed occurring in Côte d’Ivoire, Ethiopia, Uganda, Kenya, Tanzania, Zambia, and northern Angola [11].

Apart from its use in the management of TB, the stem bark of this tree is also used in the preparation of herbal remedies for the management of symptoms of bronchial infections, dysentery, malaria, jaundice, and skin infections [7, 8, 10]. The ethanol extract from the leaves of *A. coriaria* showed good antibacterial activity against several bacteria strains (*Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Salmonella typhi*) with minimum inhibitory concentrations ranging between 62.5 and 250 μg/mL [13]. However, there was no published scientific study that has validated the claimed antimycobacterial activity of *A. coriaria*. Therefore, this study was conducted to determine the cytotoxicity, *in vitro* antimycobacterial activity, and phytochemical composition of the crude extracts of the stem bark of *A. coriaria*. The binding affinities for selected molecular targets of *M. tuberculosis* together with the descriptors of pharmacokinetic and toxicity properties of the identified compounds from GC-MS analysis were also determined using *in silico* studies.

2. Materials and Methods

2.1. Plant Sample Collection and Preparation. Samples of the stem bark of *A. coriaria* were harvested from trees growing in the wild in Siaya and Kisumu counties, Western Kenya, after identification by a taxonomist. The samples were packed in a clean sack and transported to the Chemistry Laboratory, Moi University, for drying and processing. A voucher specimen (OSB/01/2020/002) was prepared and deposited at the Herbarium, Botany Department, University of Eldoret (Kenya), for authentication and reference purposes. The stem barks were chopped into small pieces and dried under shade at room temperature (25.0 ± 2.0°C) for one month until a constant mass was obtained. The dried samples were then ground using an electric grinder (Nutribullet® 600 Series), packed, and stored in clean labeled paper envelopes at room temperature until extraction.

2.2. Extraction. Solvents of analytical grade were purchased from Merck-Sigma-Aldrich and used to prepare crude extracts. Serial extraction was performed using solvents of increasing polarity in the order n-hexane, chloroform, acetone, and methanol. The pulverized sample (300 g) was soaked in 1000 mL of hexane for 72 hours with occasional shaking using a digital shaker. The mixture was then filtered through Whatman No. 1 filter paper to obtain the hexane crude extract. The n-hexane extract was concentrated using a rotary evaporator (Hahnvapor HS-2005S) at 40°C and reduced pressure. The concentrated crude extracts were dried in a desiccator over anhydrous copper (II) sulfate to constant weight at room temperature. The percentage yield (%) of the extracts was calculated using the following equation:

\[
\text{percentage yield} = \left\frac{\text{weight of dry crude extract}}{\text{weight of the powder macerated}}\right \times 100.
\]

Meanwhile, the plant residue was air-dried for 48 hours at room temperature and then macerated in 1000 mL of the next solvent (chloroform) at room temperature for 72 hours with intermittent shaking and the process of filtration and re-extraction was repeated until the final solvent (methanol). The four concentrated crude extracts were stored in clean labeled bottles at 4°C in a refrigerator until further use.

2.3. Cytotoxicity Evaluation of the Plant Extracts. The 3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide (MTT) assay was used to assess the cytotoxicity of the extracts using mammalian Vero E6 cells (ATCC CCL 81) [14]. Cryopreserved Vero E6 cells were revived by incubating them in T175 cell culture plates containing growth media at
37°C, 5% carbon dioxide supply, and 98% humidity for 24 hours. The cells were trypsinized and regrown until the required seeding density (20,000 cells/100 μL) was obtained. Vero cells were seeded in a 96 well plate at 2 × 10⁴ cells per well in columns 1, 2, 4, 5, 7, 8, 10, and 11 in Eagle’s minimum essential media (MEM) supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, 1% glucose, and 2.5% of 7.5% (w/v) sodium bicarbonate solution. Wells in rows 3, 6, 9, and 12 received only growth media and served as test extract blank. The cells were grown in 5% carbon dioxide at 37°C for 24 hours. The growth media were removed and replaced with 100 μL of maintenance media (MM). To make initial 1000 μg/mL for serial tripling dilution, a 15 μL of 10 mg/mL of each extract was added to row H of 96-well plates followed by 35 μL of MM and serial tripling dilutions carried out up to row B, representing 1000.00, 333.33, 111.11, 37.04, 12.35, 4.12, and 1.37 μg/mL, leaving row A to serve as cell control. The last 50 μL picked from row B was discarded. Rifampicin was used as a reference standard drug. For each test sample, two columns were used as a negative control (media and plant extract only). Cells were then incubated at 37°C for 48 hours after which the wells were emptied of the media. MTT (10 μL prepared at 5 mg/mL in phosphate-buffered saline) was added to all the wells and incubated for 4 hours until a purple precipitate was visible in the wells under the light microscope. Clear wells were cell-free wells or wells where cells were destroyed by the cytotoxic effect of extracts. The liquid content of the wells was aspirated off, and 100 μL of DMSO was added to dissolve the formazan crystals (attached to the wells) produced by viable cells. The absorbance was read using an ELISA plate reader at 540 nm with a reference wavelength of 720 nm. The percentage cell viability at different extracts’ concentrations was calculated using the following equation:

\[
\text{percentage cell viability} = \frac{At - Ab}{Ac - Ab} \times 100, \tag{2}
\]

where \(At\) is the absorbance value of the test compound, \(Ab\) is the absorbance value of the negative control (blank), and \(Ac\) is the absorbance value of the positive control.

The results were used to construct graphs of percentage cell viability against extract concentrations. The cytotoxic concentration of plant extract, which corresponds to 50% viability of the Vero cells (CC₅₀ value), was estimated from the graph using a linear regression equation (\(Y = aX + b\)).

2.4. Antimycobacterial Testing

2.4.1. Mycobacterial Strains and Preparation of Inoculum. Fresh middle brook 7H9 broth media supplemented with glycerol and OADC was prepared according to the manufacturer’s instructions. Preserved strains of \(M. tuberculosis\) (H37Rv) and \(Mycobacterium smegmatis\) (ATCC 607) were obtained from the TB laboratory at the Centre for Respiratory Disease Research (CRDR), Kenya Medical Research Institute, Nairobi, Kenya. \(M. smegmatis\) was used because of its nonpathogenicity, first replicating nature and genetic similarity to \(M. tuberculosis\) [15, 16]. The obtained seed stock was thawed from the frozen state (−20°C) to room temperature and diluted in a ratio of 1:1000 (v/v) with filter-sterilized broth media in a 750 mL culture bottle. The bacteria were precultured for 48 hours for \(M. smegmatis\) and 14 days for \(M. tuberculosis\) at 37°C with no shaking up to an OD₆₀₀ 0.6–0.8 (exponential phase) in filter-sterilized 7H9 media supplemented with 10% OADC, 0.2% glycerol, and 0.25% Tween 80 (20% in H₂O). The pregrown inoculum was again diluted in a ratio of 1:1000 at the time of use [17].

2.4.2. Preparation of Plant Extract Stock Solution. Each crude solvent extract (100 mg) was dissolved in 1 mL of dimethyl sulfoxide (DMSO) and vortexed for fifteen (15) minutes. Freshly prepared middle brook 7H9 broth media (9 mL) was then added to the mixture to make a 10,000 μg/mL stock solution with 1% DMSO. The solution was then filter-sterilized (0.22 μm) to obtain an extract stock solution (5 mL). Each extract was prepared fresh at the time of use.

2.4.3. Broth Microdilution Assay. Microplate Alamar blue assay (MABA) was used to determine the minimum inhibitory concentration (MIC) of the extracts in a 96-well plate twofold dilution setup [18]. The broth media 7H9 (50 μL) were added in all the wells, except the first column where the initial concentration of plant extracts was added. Each plant extract was pipetted in duplicate (100 μL of stock solution in column 1), with two rows (1st and 8th) serving as negative control and positive control. Twofold serial dilution was carried out by transferring 50 μL of the content (plant extract + broth media) of the wells of the first column to the next wells until the wells of the 12th column were reached, where 50 μL was aspirated off. An aliquot (50 μL) of the pregrown inoculum (\(M. smegmatis\) and \(M. tuberculosis\)) was separated added in all wells except the row 1 wells serving as the control. The total volume in each well was 100 μL, and the initial concentration was diluted such that the concentration of the tested extracts ranged between 5000 and 4 μg/mL. After sealing the microplates with parafilm paper, they were placed in a tight box and incubated for 48 hours for \(M. smegmatis\) and 21 days for \(M. tuberculosis\) at 37°C at the biosafety level-3 laboratory at CRDR, KEMRI. Freshly prepared resazurin blue dye (20 μL) at 0.01% in distilled water was added, and the plates were incubated again for another 24 hours. The change in colour from blue to pink indicated the growth of mycobacterium (inactivity of the plant extract) and the noncolour change indicated the inhibition of growth of mycobacterium (the activity of the plant extract). Rifampicin was used as the reference standard drug in this study. The MIC of each extract was determined as the lowest extract concentration that prevented a colour change from blue to pink. Each extract was tested in duplicate, and the mean value was calculated using Microsoft Excel.

2.5. Phytochemical Screening. Preliminary qualitative tests were conducted to determine the presence of different phytochemicals in the extract mainly saponins, alkaloids, triterpenes, tannins, flavones, coumarins, reducing sugars,
steroid glycosides, emodols, anthocyanins, and volatile oils in the extracts following standard procedures [19].

2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

2.6.1. Sample Preparation. The crude acetone and methanol that showed the highest bioactivity against the mycobacterial species were subjected to GC-MS analysis. Each extract (5 mg) was redissolved in their respective analytical grade solvents (5 mL) and shaken using a digital shaker to ensure complete dissolution. A combination of trimethylchlorosilane (TMCS) and N,O-bis(trimethylsilyl)-tri-fluoroacetamide (BSTFA) was used to derivatize the alcohols, alkaloids, amines, biogenic amines, steroids, phenols, and carboxylic acids that could be present in the samples for increased detection by the GC-MS/MS system. Excess BSTFA+1% TMSC (20 mL) was added to dissolved samples and heated at 70°C for 30 minutes to allow complete derivatization as per the manufacturer’s instructions.

2.6.2. GC-MS Sample Analysis. The derivatized samples were analyzed using an Agilent Intuvo 9000 GC system (USA) equipped with a fused silica column (Agilent Intuvo HP-5MS UI) with dimensions 30 m × 250 μm × 0.25 μm. The MS component was Agilent 7000D GC/TQ. Ultrapure helium gas (99.9995%) was used as the carrier gas at a constant flow rate of 1.1 mL/min. An electron ionization energy method with high ionization energy of 70eV was used for spectral detection with UI) with dimensions 30m × 250 μm × 0.25 μm. (Q´he MS

2.7. Fourier Transform Infrared (FTIR) Spectroscopic Analysis. FTIR spectra were acquired using a JASCO FTIR-6600 spectrometer (Japan) to determine the functional groups present in the extracts. Solid samples (1 mg) of each extract were placed on the sample holder of the FTIR spectrophotometer and scanned between 4000 and 400 cm⁻¹ to obtain the spectra that were then interpreted.

2.8. In Silico Studies. Molecular operating environment (MOE) software, version 2008.10 (Chemical Computing Group, Montreal, Canada) was used to perform in silico docking simulations. Default settings in the MOE docking simulation tool were used for docking using the London Gibbs free energy scoring function. Before docking simulations were performed, ligands and proteins were prepared, and the docking method was validated.

2.9. Ligand Preparation. A local library of compounds from A. coriaria identified by GC-MS was prepared for in silico studies. Two-dimensional structures of the molecules (ligands) were drawn using ChemBioDraw ultra software, version 12.0 (Cambridge soft), and imported into the MOE structure builder tool as SMILES string to generate 3D structures. The energy of the 3D molecules was minimized by applying the Hamiltonian MMFF94X force field. The minimized molecules were used to develop a local library for docking simulations.

2.10. Protein Preparation. The crystal structures of two key molecular targets involved in TB disease were downloaded from the protein data bank (PDB). These were polyketide synthase-13 pks13 (PDB ID: 5V3Y) and ATPase (PDB ID: 3AR4). The proteins were prepared using the LigPse tool in the MOE suite. Partial charges were added, the amino acids were protonated, and the crystal structures were sequentially minimized in three stages using the minimization protocol with default parameters. Finally, all counter ions and water molecules were deleted, and the binding sites were defined based on the cocrystallized ligands.

2.11. Docking Method Validation. The docking method was first validated by self-docking the native ligand into the binding site of the protein. Here, an induced-fit docking mode was adopted (where both the ligand and the amino acid side chains were left flexible to achieve an optimal fit). The validity of the docking method was evaluated based on the root mean square deviation (RMSD) upon superposition of the best-docked pose to the experimental native ligand conformation. The RMSD value <2Å was considered optimal. The binding affinities measured in terms of S-score in Kcal/mol were used for comparison with the binding affinities of the test ligands (identified compounds).

2.12. In Silico Docking of the Compound Library. The local library of the identified compounds was docked into the binding site of the target proteins. The resultant docking poses of the ligands were ranked based on the S-score (binding energy). In this case, the more negative the S-score, the stronger the binding affinity to the target protein. The binding affinities were compared with those of standard drugs used in TB management (isoniazid, rifampicin, and bedaquiline).

2.13. Prediction of the Drug-like Properties of the Identified Compounds. To calculate the absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties of the identified compounds from A. coriaria, the open-source tools
SwissADME (http://www.swissadme.ch/) and ADMETLab 2.0 from computational Biology & Drug Design Group (https://admetmesh.scbdd.com/) were used [21]. This software is freely available online and robustly offers up-to-date and high-quality data. ADMETLab 2.0 uses Caco2-cell (heterogeneous human epithelial colorectal adenocarcinoma cell lines) and MDCK (Madin–Darby Canine Kidney) cell models to predict oral drug absorption, skin permeability, human intestinal absorption, and transdermal drug absorption. Similarly, the program uses blood-brain barrier (BBB) penetration and plasma protein binding models to predict the distribution of the compounds. The test molecules were input as SMILES, and the properties were calculated using the algorithms [22].

2.14. Statistical Analysis. Numerical data were entered into Microsoft Excel (version 2013), and the means and standard deviations were calculated. Statistically significant differences were determined using one-way analysis of variance (ANOVA) and/or Student’s t-test followed by Dunnett’s post hoc test using GraphPad Prism (version 5.01, GraphPad Software, San Diego, California, USA). The results were presented as means ± standard deviations, while statistically significant differences were considered at p < 0.05.

3. Results

3.1. Extraction Yield, Antimycobacterial Activity, and Cytotoxicity. Methanol had the highest extraction yield (23.2%) followed by acetone (23.0%), chloroform (0.73%), and lastly hexane (0.48%). All four extracts of A. coriaria had cytotoxic concentrations greater than 1000 μg/mL against Vero E6 cells. When compared to rifampicin (CC50 = 520.02 ± 40.11), all the other extracts were relatively safer with statistically significant cytotoxic concentrations (Table 1). Acetonic and methanolic extracts of A. coriaria had similar antimycobacterial activity (MIC = 1250.0 ± 0.0 μg/mL) against M. smegmatis, whereas the acetonic extract was more active (MIC of 937.0 ± 442.0 μg/mL) than the methanolic extract (MIC = 2500 ± 0.0 μg/mL) against M. tuberculosis (Table 1). Both the hexane and chloroform extracts were inactive against both M. tuberculosis and M. smegmatis. Rifampicin had superior activity than the four extracts against the two mycobacterial strains (p < 0.05).

3.2. Phytochemical Screening Results. The most abundant phytochemicals were tannins, triterpenes, flavonoids, alkaloids, anthocyanins, saponins, steroid glycosides, and coumarins. Emodins were absent in all the extracts, whereas anthracenosides and volatile oils were absent in the methanol extracts. The acetone extract had the highest phytochemical diversity followed by methanol extract, chloroform extract, and lastly hexane extract (Table 2).

3.3. GC-MS Results. The GC-MS chromatograms of the acetonic and methanolic extracts revealed a total of 28 and 19 compounds, respectively, that corresponded to the authentic compounds in the NIST library (Table 3 and Figure 1). The most abundant compounds in the acetonic extract included 1,2-benzenedicarboxylic acid, butyl 2-methylpropyl ester (17), 9,12-octadecadienoic acid (Z,Z)-, methyl ester (19), methyl stearate (20), hexadecanoic acid, methyl ester (15), 2,2,4-trimethyl-1,3-pentanedioldisobutyrate(7), hydroquinone(1), 7-hydroxy-3′-methoxylyavone, trimethylsilyl ether (2), docosanoic acid, methyl ester (24), tetracosanoic acid, and methyl ester (25) (Figure 2). The most abundant compounds in the methanolic extract were hexadecanoic acid, methyl ester (15), 2H-pyran-3,4,5-triol,tetrahydro-2-methoxy-6-methyl-(31),beta-D-glucopyranose,1,6-anhydro-(33), dibutyl phthalate (39), 9-octadecenoic acid (Z)-, methyl ester (40), and methyl stearate (20). Of all the identified compounds, three compounds [hydroquinone (1), hexadecanoic acid, methyl ester (15), and dibutyl phthalate (39)] have been reported to possess antibacterial activity (Figure 2).

3.4. FTIR Analysis. FTIR analysis of the crude acetone and methanol extracts of A. coriaria showed peaks that corresponded to different functional groups present in the respective extract. In the acetone extracts, the peaks at 1027.87 and 1204.32 cm⁻¹ are for C-O bonds, the peak at 1370.17 cm⁻¹ is for C-O-H bonds, peak at 1604.48 cm⁻¹ is for C=C or C=O, and peak 3208.98 cm⁻¹ is for O-H (Figure 3(a)). In the methanol extracts, the peak at 1051.01 cm⁻¹ is for C-O bonds, the peak at 1436.63 cm⁻¹ is for C=C, the peak at 1692.23 cm⁻¹ is for C=C or C=O, and the peak at 3161.72 cm⁻¹ is for O-H (Figure 3(b)). All these functional groups that were identified in the FTIR analysis correspond to the different compounds identified during the GC-MS analysis (Figure 2).

3.5. In Silico Screening Results

3.5.1. Docking Method Validation. Docking of the native ligand into the binding sites of the molecular targets resulted in root mean square deviation (RMSD) values of less than 2 Å (Table 4). An RMSD of less than 2 Å implies that the docking method was reproducible and accurate (Figures 4 and 5).

3.5.2. Binding Affinities of the Identified Compounds from A. coriaria for Polyketide Synthase and ATP Synthase Enzymes. Seven compounds identified by GC-MS analysis had better binding affinities than the two drugs (Isoniazid and rifampicin), which form the backbone of any first-line TB regimen. Five compounds had better binding affinities than bedaquiline (the standard drug known to block the mycobacterial ATP synthase enzyme) (Table 5). A visual inspection of the binding interactions of the identified compounds suggests that the ligand interacted via hydrogen bonding with amino acid Asn 1640 of the binding site of the PK13 as well as hydrophobic interactions with the amino acid residues in the binding site (Figure 6). On the other hand, visual inspection of the binding interactions of the
Table 1: Extraction yield, minimum inhibitory, and cytotoxic concentrations of the extracts of *A. coriaria* stem bark.

| Extract      | Percentage yield (%) | Minimum inhibitory concentration (mg/mL) | Cytotoxic concentrations (μg/mL) |
|--------------|----------------------|----------------------------------------|----------------------------------|
| Hexane       | 0.48                 | NA                                     | >1000a                           |
| Chloroform   | 0.73                 | NA                                     | >1000a                           |
| Acetone      | 23.0                 | 1250 ± 0.0a                           | 937 ± 442a                      |
| Methanol     | 23.2                 | 1250 ± 0.0a                           | 2500 ± 0.0a                     |
| Rifampicin   | —                    | 15 ± 0.0                              | 4 ± 0.0                          | 520.02 ± 40.11 |

Note: *P* < 0.01 for extract vs rifampicin; NA: not active.

Table 2: Results of the phytochemical screening of stem bark extracts of *A. coriaria*.

| Secondary metabolite | Hexane | Chloroform | Acetone | Methanol |
|----------------------|--------|------------|---------|----------|
| Saponins             | –      | –          | ++      | +        |
| Tannins              | –      | –          | +++     | +++      |
| Alkaloids            | +      | ++         | +       | ++       |
| Coumarins            | ++     | +          | +++     | +        |
| Steroid glycosides   | –      | –          | +       | +        |
| Triterpenes          | +      | +++        | +++     | +        |
| Flavonoids           | +      | ++         | +++     | +        |
| Emodols              | –      | –          | –       | –        |
| Anthocyanins         | –      | –          | +++     | ++       |
| Anthracenosides      | –      | –          | –       | –        |
| Reducing sugars      | –      | –          | +++     | ++       |
| Volatile oils        | +++    | +          | –       | –        |

Note: +++ (highly present), ++ (moderately present), + (little/traces present), and – (absent).

Table 3: Chemical compounds identified in the acetone and methanol extracts of *A. coriaria* stem bark using GC-MS/MS analysis.

| RT (min) | Compound name                                           | Chemical structure | Molecular formula | CAS#               | Match factor | Area % |
|----------|---------------------------------------------------------|--------------------|-------------------|--------------------|--------------|--------|
| 8.667    | Hydroquinone (1)                                        | ![Chemical structure](1.png) | C₆H₆O₂            | 123-31-9          | 71.5         | 10.91  |
| 9.1668   | Hexanal, (2,4-dinitrophenyl) hydrazine (2)             | ![Chemical structure](2.png) | C₁₂H₁₆N₄O₄       | 1527-97-5         | 52.5         | 0.45   |
| 9.2805   | 7-Hydroxy-3′-methoxyflavone, trimethylsilyl ether (3)   | ![Chemical structure](3.png) | C₁₉H₂₀O₄Si       | 1000448-98-1      | 52.2         | 3.65   |
| 10.5152  | Alpha-d-glucofuranose, 6-amino-6-deoxy-1,2: 3,5-bis-O-(1-methylethylidene) (4) | ![Chemical structure](4.png) | C₁₂H₂₂NO₅        | 34322-93-5        | 53.8         | 4.41   |
| 12.6822  | Octadecanoic acid, 9,10-dichloro-, methyl ester (5)    | ![Chemical structure](5.png) | C₁₉H₃₆Cl₂O₂      | 33094-27-8        | 50.4         | 0.6    |
| 13.6985  | 3a,9b-Dimethyl-1,2,3a,4,5,9b-hexahydrocyclopenta[a] naphthalen-3-one (6) | ![Chemical structure](6.png) | C₁₅H₁₆O      | 76803-93-5        | 69.2         | 3.29   |
| RT (min) | Compound name | Chemical structure | Molecular formula | CAS# | Match factor | Area % |
|---------|---------------|--------------------|-------------------|------|--------------|--------|
| 14.4482 | 2,2,4-Trimethyl-1,3-pentanediol diisobutyrate (7) | | C_{16}H_{30}O_{4} | 6846-50-0 | 75.8 | 22.1 |
| 15.0766 | 1H-Indene, 2,3-dihydro-4,5,7-trimethyl (8) | | C_{12}H_{16} | 6682-06-0 | 51.7 | 0.54 |
| 17.0349 | 4,5-Dihydro-3-(4-pyridinyl)-2H-benz(g)indazole (9) | | C_{16}H_{13}N_{3} | 52837-55-5 | 57.4 | 0.96 |
| 18.8234 | 3,3,4-Tricyano-4a-methyl-2-phenyl-2,5,6,7-tetrahydro-1-benzopyran-4-carboxamide (10) | | C_{20}H_{18}N_{4}O_{2} | 1000459-39-9 | 52.1 | 0.98 |
| 19.5301 | N,N′-Ethylenebis(2-[2-hydroxyphenyl]glycine) (11) | | C_{18}H_{20}N_{2}O_{6} | 1170-02-1 | 55.1 | 1.03 |
| 20.0803 | 2-Myristoyl pantetheine (12) | | C_{25}H_{44}N_{2}O_{6}S | 1000111-63-3 | 55.1 | 1.48 |
| 21.4324 | 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl)ester (13) | | C_{16}H_{22}O_{4} | 84-69-5 | 66.1 | 3.33 |
| 22.3127 | 7-Hydroxy-6,9a-dimethyl-3-methylene-decahydro-azuleno[4,5-b]furan-2,9-dione (14) | | C_{17}H_{20}O_{4} | 1000296-15-9 | 51.9 | 0.29 |
| 22.833 | Hexadecanoic acid, methyl ester (15) | | C_{18}H_{34}O_{2} | 112-39-0 | 88.3 | 49.44 |
| 23.4149 | Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, methyl ester (16) | | C_{18}H_{28}O_{3} | 6386-38-5 | 59.3 | 3 |
| 23.8606 | 1,2-Benzenedicarboxylic acid, butyl 2-methylpropyl ester (17) | | C_{16}H_{22}O_{4} | 17851-53-5 | 84.6 | 100 |
| 25.1066 | Hexadecanoic acid, 14-methyl-, methyl ester (18) | | C_{18}H_{36}O_{2} | 2490-49-5 | 67.6 | 2.28 |
| 26.416 | 9,12-Octadecadienoic acid (Z,Z)-, methyl ester (19) | | C_{18}H_{34}O_{2} | 112-63-0 | 87.8 | 46.92 |
| 26.9327 | Methyl stearate (20) | | C_{19}H_{38}O_{2} | 112-61-8 | 82.8 | 21.11 |
| RT (min) | Compound name | Chemical structure | Molecular formula | CAS# | Match factor | Area % |
|----------|---------------|--------------------|-------------------|------|--------------|--------|
| 28.0987  | Normorphine, 2TMS derivative (21) | ![Chemical structure](image1) | C_{22}H_{33}NO_3Si_2 | 55319-88-5 | 52.2 | 1.41 |
| 29.8072  | Eicosanoic acid, methyl ester (22) | ![Chemical structure](image2) | C_{21}H_{42}O_2 | 1120-28-1 | 67.8 | 6.17 |
| 30.2999  | Octadecanal, 2-bromo- (23) | ![Chemical structure](image3) | C_{18}H_{35}BrO | 56599-95-2 | 60.8 | 1.39 |
| 32.1471  | Docosanoic acid, methyl ester (24) | ![Chemical structure](image4) | C_{23}H_{46}O_2 | 929-77-1 | 67.8 | 5.77 |
| 34.5468  | Tetracosanoic acid, methyl ester (25) | ![Chemical structure](image5) | C_{25}H_{50}O_2 | 2442-49-1 | 67.5 | 6.68 |
| 36.4072  | Thiazolo [3,2-a]benzimidazol-3(2H)-one, 6,8-dimethyl-2-[[2-(trifluoromethyl)phenyl]methylidene] (26) | ![Chemical structure](image6) | C_{19}H_{13}F_3N | 349497-82-1 | 56.2 | 3.06 |
| 37.1967  | L-Leucine, N-(2-chloroethoxycarbonyl)-N-methyl-pentadecyl ester (27) | ![Chemical structure](image7) | C_{25}H_{48}CINO_4 | 1000328-52-5 | 50.3 | 0.09 |
| 38.9061  | 5H-Cyclohepta[b]pyridine-3-carbonitrile, 6,7,8,9-tetrahydro-2-amino-4-(4-fluorophenyl) (28) | ![Chemical structure](image8) | C_{17}H_{16}FN_3 | 327098-56-6 | 50.5 | 0.2 |

**Methanolic extract**

| RT (min) | Compound name | Chemical structure | Molecular formula | CAS# | Match factor | Area % |
|----------|---------------|--------------------|-------------------|------|--------------|--------|
| 7.3899   | Methyl 3-hydroxytetradecanoate (29) | ![Chemical structure](image9) | C_{15}H_{30}O_3 | 55682-83-2 | 56.6 | 3.27 |
| 8.3156   | 9-(3-Fluoro-phenyl)-12-imino-10,11-dioxo-tricyclo[6.2.2.0(1,6)]dodecane-7,7,8-tricarbonitrile (30) | ![Chemical structure](image10) | C_{13}H_{15}FN_4O_2 | 1000296-03-2 | 53.4 | 1.12 |
| 9.1287   | 2H-Pyran-3,4,5-triol, tetrahydro-2-methoxy-6-methyl (31) | ![Chemical structure](image11) | C_{7}H_{14}O_5 | 14009-07-5 | 63 | 1.44 |
| 10.9244  | Doconexent (32) | ![Chemical structure](image12) | C_{22}H_{32}O_2 | 6217-54-5 | 51.8 | 0.23 |
| 11.9629  | Beta-D-Glucopyranose, 1,6-anhydro (33) | ![Chemical structure](image13) | C_{6}H_{10}O_5 | 498-07-7 | 71.7 | 14.44 |
| 12.8206  | Benzoic acid, 4-(acetyloxy)-3-methoxy-, methyl ester (34) | ![Chemical structure](image14) | C_{11}H_{12}O_5 | 35400-19-2 | 64.6 | 4.02 |
| 13.5814  | 1-Oxaspiro[4.5]decan-3-carboxylic acid, 2-oxo-4-cyano-, methyl ester (35) | ![Chemical structure](image15) | C_{13}H_{17}NO_4 | 140650-86-8 | 56.5 | 1.01 |
ligands with the amino acids in the binding site of ATP synthase suggested that the ligand formed hydrophobic interactions with the close contact amino acid residues (Figure 7).

3.6. **Descriptors of Pharmacokinetic and Toxicity.**

Descriptors of pharmacokinetic and toxicity properties of the top docked compounds were calculated to predict and give an insight into the drug-like properties of the compounds. These parameters can be used to guide future optimization of the promising compounds into leads by focusing on those compounds with optimum ADMET properties. Among the pharmacokinetic descriptors that were calculated included water solubility, human intestinal absorption, plasma protein binding (PPB), blood-brain barrier (BBB) penetration, CYPP450 inhibition, volume of distribution (VD), clearance, half-life,

| RT (min) | Compound name | Chemical structure | Molecular formula | CAS# | Match factor | Area % |
|----------|---------------|--------------------|-------------------|------|--------------|--------|
| 14.454 | 2,2,4-Trimethyl-1,3-pentanediol diisobutyrate (7) | ![Chemical structure](image1) | C<sub>16</sub>H<sub>30</sub>O<sub>4</sub> | 6846-50-0 | 72.1 | 11.82 |
| 17.3793 | Isoquinoline, 1-[3-methoxy-5-hydroxybenzyl]-1,2,3,4-tetrahydro-6-methoxy (36) | ![Chemical structure](image2) | C<sub>18</sub>H<sub>32</sub>NO<sub>3</sub> | 84230-26-2 | 59.5 | 2.76 |
| 21.4361 | 1,2-Benzenedicarboxylic acid, butyl octyl ester (37) | ![Chemical structure](image3) | C<sub>20</sub>H<sub>30</sub>O<sub>4</sub> | 84-78-6 | 56.1 | 0.71 |
| 22.8455 | Hexadecanoic acid, methyl ester (15) | ![Chemical structure](image4) | C<sub>17</sub>H<sub>34</sub>O<sub>2</sub> | 112-39-0 | 85.1 | 38.26 |
| 23.4029 | Benzenamine, N,N’-(1,2-dimethyl-1,2-ethanediylidene)bis(2,6-dimethyl (38) | ![Chemical structure](image5) | C<sub>20</sub>H<sub>24</sub>N<sub>2</sub> | 49673-40-7 | 54.1 | 0.6 |
| 23.8634 | Dibutyl phthalate (39) | ![Chemical structure](image6) | C<sub>16</sub>H<sub>22</sub>O<sub>4</sub> | 84-74-2 | 82.6 | 46.72 |
| 25.107 | Hexadecanoic acid, 14-methyl-, methyl ester (18) | ![Chemical structure](image7) | C<sub>18</sub>H<sub>36</sub>O<sub>2</sub> | 2490-49-5 | 58 | 1.05 |
| 26.5203 | 9-Octadeconoic acid (Z)-, methyl ester (40) | ![Chemical structure](image8) | C<sub>19</sub>H<sub>34</sub>O<sub>2</sub> | 112-62-9 | 89.9 | 100 |
| 26.938 | Methyl stearate (20) | ![Chemical structure](image9) | C<sub>19</sub>H<sub>36</sub>O<sub>2</sub> | 112-61-8 | 84.7 | 15.16 |
| 27.9188 | 7,10,13-Eicosatrienoic acid, methyl ester (41) | ![Chemical structure](image10) | C<sub>21</sub>H<sub>36</sub>O<sub>2</sub> | 30223-51-9 | 58.5 | 1.57 |
| 30.3004 | Ethanol, 2-(9,12-octadecadienyloxy)-, (Z,Z) (42) | ![Chemical structure](image11) | C<sub>20</sub>H<sub>30</sub>O<sub>2</sub> | 17367-08-7 | 53.4 | 0.92 |
| 32.4456 | 3′,8,8′-Trimethoxy-3-piperidyl-2,2′-binaphthalene-1,1′,4,4′-tetrone (43) | ![Chemical structure](image12) | C<sub>28</sub>H<sub>23</sub>NO<sub>7</sub> | 127611-84-1 | 51.9 | 0.86 |
and skin permeation. On the other hand, the toxicity parameters that were calculated included AMES toxicity, hERG blockers, hepatotoxicity, and skin sensitization (Table 6).

4. Discussion

Methanol and acetone had significantly higher yields than hexane and chloroform because of their high and intermediate polarity that allows the extraction of more compounds with intermediate to high polarity. These results are in line with the known behavior that polar solvents extract more compounds than nonpolar solvents. Therefore, the results suggest that the stem bark of *A. coriaria* contains more polar extractable phytochemicals than their nonpolar counterparts. In a related study, ethanol, a solvent of comparable polarity to methanol had the highest yield in the extraction of phytochemicals from the leaves of *A. coriaria* [13].

4.1. Cytotoxicity. The National Cancer Institute classified chemicals according to their cytotoxicity as follows: IC\textsubscript{50} \leq 20 \mu g/mL = highly cytotoxic, IC\textsubscript{50} 21–200 \mu g/mL = moderately cytotoxic, IC\textsubscript{50} 201–500 \mu g/mL = weakly cytotoxic, and IC\textsubscript{50} > 501 \mu g/mL = noncytotoxic [23]. The cytotoxicity results imply that the extracts had acceptable cytotoxicity profiles against Vero E6 since their cytotoxic concentrations were well above the cut-off limit of 500 \mu g/mL. This probably suggests that all the stem bark extracts (hexane, chloroform, acetone, and methanol) of *A. coriaria* lack inherent toxic phytochemicals that can destroy mammalian cells at normal concentrations. In line with this study, the methanol and water stem bark extracts of *A. coriaria* were nontoxic (CC\textsubscript{50} > 500 \mu g/mL) against human embryonic lung fibroblast (HEL) cells [24]. In contrast, the stem bark ethanol and DMSO extracts of *A. coriaria* harvested in central Uganda had high cytotoxicity against the human glioblastoma cell line (U87.CD4.CXCR4) with CC\textsubscript{50} of 6.4 and <4 \mu g/mL, respectively [25]. The difference could be attributed to the fact that in the latter study, a different cell line was used, and also the plant samples were harvested from a different geographical zone, which probably could have resulted in differences in the composition and abundance of secondary metabolites. Since *A. coriaria* is used in the management of TB, which is a chronic disease that develops and heals slowly, subacute and subchronic toxicity studies are needed to determine the long-term effects of the metabolism and distribution of these plant extracts.

![Figure 1: Chromatogram for the GC-MS/MS analysis of the crude acetone (a) and methanol (b) extract of *Albizia coriaria*. Acquisition parameters: oven, initial temp 70°C for 2 min, ramp 25°C/min to 150°C, 3°C/min to 200°C, 8°C/min to 280°C hold for 10 minutes. Injection auto 280°C, volume = 1 \mu L; split = 10:1; carrier gas = He; transfer temp 280°C; source temp 280°C; scan 50–600 Da; column: 30m × 250 \mu m × 0.25 \mu m.](image-url)
Figure 2: Chemical structures of the most abundant and bioactive compounds identified by the GC-MS analysis in the acetonic and methanolic extract of *Albizia coriaria*.

Figure 3: Continued.
repeated administration of the bioactive plant extracts on hematological, biochemical, and histological parameters [26].

4.2. Antimycobacterial Activity. The observed bioactivity of the acetone and methanol extracts implies that compounds of intermediate to high polarity are responsible for the inhibition of the growth of mycobacterial species. Although we could not ascertain the exact phytochemicals responsible for the bioactivity at this stage, it is highly plausible that the observed activity is due to compound(s) present in this plant such as triterpenes, alkaloids, and flavonoids. Acacic acid lactone, lupeol, lupenone, (+)-catechin, betulinic acid, and benzyl alcohol were previously isolated from the ethyl acetate extract of the stem bark of \textit{A. coriaria} [12]. Additionally, flavonoids, terpenoids, and alkaloids isolated from members of the family Fabaceae have been reported to possess the antimycobacterial activity [27]. The inactivity of the hexane and chloroform extracts is because these solvents extract largely nonpolar compounds. Yet nonpolar compounds have been reported to be generally inactive against several pathogens including mycobacterium [28]. The higher antimycobacterial activity of acetone extract than the methanol extract could probably be because the acetonic extract had a wider variety of phytochemicals, moreover, in slightly higher concentrations than the methanolic extract. The inferior activity of the extracts to rifampicin could probably be attributed to the crude nature of the samples, which results in matrix interferences that reduce the actual quantity of the active ingredients at the target to cause the desired activity. It is also possible that some of the compounds in the multicomponent herbal extract could also have the antagonistic effect that lowers the antimycobacterial activity of the total crude. To the best of our knowledge, this is the first study to report the \textit{in vitro} antimycobacterial activity of \textit{A. coriaria}. However, other species from genus Albizia such as \textit{A. adianthifolia} have been reported to possess antimycobacterial activity [29].

4.3. Phytochemical Analysis. The phytochemicals present are secondary metabolites of various pathways that occur in many plant species of family Fabaceae. Some of these phytochemicals have been reported to possess good pharmacological activities against TB and hence could be responsible for the antimycobacterial properties of this plant [13]. The diverse phytochemical composition of acetone extracts is due to its intermediate polarity that allows acetone to extract a wide range of phytochemicals of intermediate and slightly high polarity [19]. Derivatization of less volatile and thermally labile phytochemicals using appropriate derivatizing agents is a method of increasing the detection of phytochemicals during GC-MS analysis. In this study, silylation using BSTFA and TMCS was used to make the phytochemicals with - OH, -COOH, =NH, -NH\textsubscript{2}, and -SH groups more volatile, less polar, and more thermally stable. Although BSTFA is a strong silyl donor, its donor strength is increased in the presence of TMCS [30]. The derivatizing agent displaces the active protons in the functional groups as shown in Figure 8.

![Figure 3: FTIR spectrum for the crude acetone (a) and methanol (b) stem bark.](image)

| Target (PDB ID) | RMSD | Binding energy (kcal/mol) |
|----------------|------|--------------------------|
| Polyketide synthase 13 (5V3Y) | 0.8288 | −28.2653 |
| ATP synthase (3A4R) | 0.7076 | −37.9922 |
All the functional groups that were identified during the FTIR analysis correlated well with the compounds identified during the GC-MS (Figure 2). The major chemical compounds identified from acetone and methanol crude stem bark extracts *A. coriaria* are secondary metabolites that form an integral part of the plants’ defense systems. These secondary metabolites have been reported to have significant pharmacological properties and thus used in the management of several human and animal diseases. For example, hydroquinone, which was identified to be present in this plant was previously reported to have antimycobacterial activity with MIC ranging between 12.5 and 50 μg/mL against susceptible *M. tuberculosis* (strains H37Ra and H37Rv) and resistant strains [31]. Hexadecanoic acid also identified to be present in this plant has been reported to have antimicrobial activity, and antioxidant, antifibrinolytic, nematicide, pesticide, 5-alpha-reductase inhibitor, anti-androgenic, hypocholesterolemia, and hemolytic properties [33]. Dibutyl phthalate has been previously reported to have the antimicrobial activity against an array of bacterial and fungal pathogens. These include *Staphylococcus epidermidis, Streptococcus pneumoniae, Escherichia coli, Micrococcus luteus, Klebsiella pneumoniae, Shigella flexneri, Vibrio cholerae, and P. aeruginosa* [34–37].

These bioactivities suggest that the stem bark of *A. coriaria* has the potential to provide novel molecules for the development of antimycobacterial and antibacterial agents. Apart from acting as marker compounds for bioactivity, the
Figure 5: Maps of the pose of cocrystalized ligand in the binding of ATP synthase (a) and redocked pose of cocrystalized ligand (maroon colour) superposed on the native ligand (grey colour) (b). Interactions of cocrystalized ligand with amino acid residues in the binding of ATP synthase (c). Interactions of the cocrystalized ligand with amino acid residues in the binding site of ATP synthase (d).

Table 5: Top five docked ligands from those identified by GC-MS analysis on two protein targets.

| SN | Polyketide synthase | Binding energy (kcal/mol) | ATP synthase | Binding energy (kcal/mol) |
|----|---------------------|---------------------------|--------------|--------------------------|
| 1  | 3′,8′,8′-Trimethoxy-3-piperidyl-2,2′-binaphthalene-1,1′,4,4′-tetrone (43) | −26.8626 | l-Leucine, N-(2-chloroethoxycarbonyl)-N-methyl-, pentadecyl ester (27) | −28.7742 |
| 2  | l-Leucine, N-(2-chloroethoxycarbonyl)-N-methyl-, pentadecyl ester (27) | −22.1684 | Tetracosanoic acid, methyl ester (25) | −28.3306 |
| 3  | Docosanoic acid, methyl ester (24) | −21.8569 | 1,2-Benzenedicarboxylic acid, butyloctyl ester (37) | −26.6023 |
| 4  | Eicosanoic acid, methyl ester (22) | −21.2508 | Docosanoic acid, methyl ester (24) | −25.9241 |
| 5  | 7-Hydroxy-3′-methoxyflavone, trimethylsilyl ether (3) | −20.1252 | Eicosanoic acid, methyl ester (22) | −24.0608 |
| 6  | Bedaquiline | −24.0017 | Bedaquiline | −22.9042 |
| 7  | Isoniazid | −10.8307 | Isoniazid | −11.6257 |
| 8  | Rifampicin | −17.5541 | Rifampicin | −18.5886 |
identified compounds can as well be used during chemical fingerprinting and profiling of chemical products especially pharmaceuticals prepared from this plant.

4.4. Molecular Docking Studies. In mycobacterium, polyketide-13 synthase (pks-13) catalyzes the condensation reaction (last step) in the biosynthesis of mycolic acid biosynthesis to form oxomycolic acid intermediate, which is then reduced by mycolyl reductase to form mycolic acid. Mycolic acids are long \( \alpha \)-alkyl, \( \beta \)-hydroxy fatty acids consisting of 60–90 carbon atoms required for the formation of the mycobacterial cell wall and hence maintenance of cell
The interactions of the mycolic acids with other cell wall components make the mycobacterial cell walls very unique and contribute to the challenges associated with mycobacterium especially its pathogenesis, persistence, and chemotherapy. Given the critical role of mycolic acids in mycobacterium cell viability and pathogenesis, enzymes integrity.

### Table 6: Descriptors of absorption, distribution, metabolism, elimination, and toxicity (ADMET) of top docked compounds.

| Properties | 43 | 27 | 24 | 22 | 3 | 25 | 37 | Acceptable values |
|------------|----|----|----|----|---|----|----|-------------------|
| **Absorption** |    |    |    |    |    |    |    |                   |
| Water solubility (log S) | −5.25 | −7.22 | −7.08 | −6.47 | −7.10 | −7.80 | −4.91 | −2 to −4 |
| CaCO₂ permeability (log P app in 10⁻⁶) (cm/s) | −4.920 | −4.722 | −5.047 | −4.964 | −4.863 | −5.103 | −4.673 | >−5.15 |
| P-gp substrate | No | No | No | No | No | No | No | No |
| P-gp I inhibitor | No | No | No | Yes | No | Yes | No | No |
| Log Kp (skin permeation) (cm/s) | −6.49 | −2.32 | −1.22 | −1.69 | −5.15 | −0.63 | −4.13 | <−5.0 |
| F₂₀% | Low | High | High | High | Low | High | High | High |
| F₃₀% | High | High | High | High | High | High | High |
| **Distribution** |    |    |    |    |    |    |    |                   |
| PPB (%) | 91.59 | 98.12 | 96.99 | 97.16 | 99.45 | 97.06 | 97.88 | <90 |
| BBB permeability | No | No | No | No | No | No | Yes | No |
| VD (L/kg) | 0.430 | 1.265 | 1.577 | 3.112 | 2.906 | 3.814 | 1.367 | 0.04–20 |
| Fraction unbound in plasma (%) | 0.856 | 2.066 | 1.763 | 1.311 | 0.912 | 1.095 | 1.608 | >5 |
| **Metabolism** |    |    |    |    |    |    |    |                   |
| CYP1A2 inhibitor | No | Yes | Yes | Yes | Yes | Yes | Yes | No |
| CYP2C19 inhibitor | No | No | No | Yes | No | No | No | No |
| CYP2C9 inhibitor | Yes | Yes | No | No | Yes | No | Yes | No |
| CYP2D6 inhibitor | No | No | No | No | Yes | No | Yes | No |
| CYP3A4 inhibitor | Yes | No | Yes | No | Yes | No | Yes | No |
| CYP1A2 substrate | Yes | No | No | No | Yes | No | No | No |
| CYP2C19 substrate | No | No | No | No | No | No | Yes | No |
| CYP2C9 substrate | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| CYP2D6 substrate | No | No | No | No | Yes | No | No | No |
| CYP3A4 substrate | No | No | No | No | No | No | Yes | No |
| **Elimination** |    |    |    |    |    |    |    |                   |
| Total clearance (mL/min/kg) | 3.78 | 4.35 | 4.63 | 4.65 | 3.41 | 15.96 | 10.38 | >5 |
| Probability that half-life is less than 3 hours | 0.018 | 0.056 | 0.098 | 0.143 | 0.116 | 0.014 | 0.123 | <0.3 |
| **Toxicity** |    |    |    |    |    |    |    |                   |
| Carcinogenicity (AMES toxicity) | Yes | No | No | No | No | No | No | No |
| Cardiovascular toxicity (hERG blockers) | No | No | No | No | No | No | No | No |
| Hepatotoxicity | Low | No | No | No | No | No | No | No |
| Skin sensitization | No | Yes | Yes | Yes | Yes | Yes | Yes | No |
| **Physicochemical properties (Lipinski Rule #Violations)** |    |    |    |    |    |    |    |                   |
| Number of hydrogen bond donors (N-H, O-H): 0 to 7 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| Number of hydrogen bond acceptors (N, O): 0 to 12 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| Molecular weight: 100–600 Da | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| The logarithm of the n-octanol/water distribution coefficient (log P): 0 to 3 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |

VD: volume of distribution, PPR: plasma protein binding, CL: renal clearance, F₂₀%: human oral bioavailability 20%, F₃₀%: human oral bioavailability 30%, and numbers correspond to the top docked compounds from Table 5. Acceptable values are according to software https://admetmesh.scbdd.com.
involved in mycolic acids biosynthesis, such as pks-13 present novel targets for drug development [38]. On the other hand, mycobacterial ATP synthase is another validated drug target and compounds inhibiting this enzyme are promising drug candidates [39]. A unique feature of M. tuberculosis ATP synthase is the suppression of the ATP hydrolyase activity and its inability to establish a proton gradient. This is thought to be an adaptive mechanism to prevent wastage of ATP during low oxygen conditions [40]. Bedaquiline, a newly approved antitubercular drug, binds to ATP synthase inhibiting it from releasing energy for the mycobacterial cellular activity resulting in the death of the mycobacterium [41].

The seven identified compounds that had good binding affinities for the pks-13 and ATP synthase provide insight into their potential to inhibit vital metabolic processes in the mycobacteria. For example, 3',8,8'-tri-methoxy-3-piperidyl-2,2'-binaphthalene-1,1',4,4'-tetrone and l-leucine, 1-(2-chloroethoxycarbonyl)-N,N-methyl-, pentadecyl ester blocked the pks-13 and ATP synthase with binding energies of -26.8626 and -28.7742 (kcal/mol). In a related study to evaluate the antimycobacterial activity of a series of 3,5-disubstituted-1,2,4-oxadiazole derivatives, pks-13 was used as a putative molecular target [38]. Like in our study, the ligands showed comparable binding affinities with the standard drugs. In contrast to our study, the main stabilizing interactions between the compounds and the enzyme were π-π interactions with the aromatic amino acid residues Phe1590, Tyr1637, Phe1585, Tyr1674, Phe1670, and the catalytic His1699 with intermittent hydrogen bonding with Ser1636 and Asn1640 [38]. In another study, five new benzofuran derivatives were reported to have sufficient binding affinity for the pks-13 synthase with an alternative binding mode to the active site [42]. All the top five ligands that inhibited the ATP synthase had at least long alkyl chains with a terminal carboxylic acid group. They therefore effectively interact with the amino acids in the catalytic site and dissipate the proton motive force (PMF), thereby decreasing the synthesis of ATP through uncoupled oxidative phosphorylation. The antimycobacterial activity of SQ109 (sequella), an antitubercular drug in phase II clinical trials, was elucidated to be due to its highly α-branched aliphatic moieties, which are more effective in suppressing the PMF and thus inhibit the synthesis of ATP [40]. Hydrolysis of pyrazinamide (a standard drug for TB) to pyrazinoic acid resulted in the dissipation of the PMF and hence the inhibition of ATP synthesis in M. tuberculosis [40]. Thus, some of the identified compounds contain carboxylic acids on long alkyl groups, and it is highly probable that the two synergistically interact with various amino acids in the catalytic site of ATP synthase and inhibit the PMF, thereby decreasing ATP biosynthesis.

4.5. Pharmacokinetic and Toxicity Evaluation (ADMET Descriptors). All the compounds had acceptable physicochemical properties with acceptable violations of the Lipinski rules except for the logarithm of the n-octanol/water distribution coefficient (Log P), which was violated by compounds 27, 22, 3, 25, and 37 (Log P greater than 3). Additionally, all the compounds had moderate water solubility with their log S ranging between −4.9 and −7.8 (optimum solubility ranges between −2 and −4.0). With exception of compounds 43 and 37, the rest had low oral gastrointestinal absorption. This implies that these compounds might need optimization to increase their water solubility and hence absorption as they need to first dissolve in water to be absorbed [22]. All the compounds were not substrates of the P-glycoproteins (P-gp). On the other hand, with exception of compounds 43 and 37, the rest were also not inhibitors of the P-glycoproteins. P-Glycoproteins are efflux pumps that actively pump drugs out of the cells, thereby decreasing their intracellular concentrations. They particularly protect the central nervous system from accumulating xenobiotics. Physiologically, P-gp has a fundamental role in the secretory processes [22]. All the compounds had good skin permeation except compound 43, which had a skin permeation value of greater than −5 cm/s.

All the compounds had high plasma protein binding (greater than 90%) and hence high chances of adsorbing onto the plasma proteins. This might contribute to these compounds having a small therapeutic index and hence high chances of toxicity. The compounds also showed acceptable volumes of distribution. All the compounds had a low fraction unbound in plasma implying that there are less likely to efficiently transverse the cellular membranes and reach the
target sites. All the compounds showed the inability to penetrate through the blood-brain barrier except compound 37 implying that they could not reach the brain tissues. The blood–brain barrier prevents small molecules (98%) and larger molecules (100%) from entering the central nervous system (CNS). However, it allows transport of only water- and lipid-soluble molecules and selective transport of some molecules and drugs especially those that are substrates of active transporters such as glucose and P-gp transporters [43].

Compound 3 showed inhibitory potential on all the cytochrome P450 (CYP 450) enzymes, whereas compounds 43, 27, and 37 showed the inhibition of CYP 2C9 and CYP3A4. CYP 1A2 was inhibited by all the compounds except compound 43. All compounds were substrates to CYP2C9, whereas compound 3 was in addition a substrate for CYP2D6 and CYP 1A62. CYP 450 enzymes are mixed functional oxidases located majorly in the liver and intestine and are responsible for the metabolism of about 60% of xenobiotics such as drugs, steroids, carcinogens, and eicosanoids. They mainly catalyze reductions, oxidation, hydrolysis, and epoxidation reactions that result in the transformation of the parent compound into either less or more toxic metabolites. Compounds that inhibit CYP450 can lead to serious drug-drug interactions that might result in toxicity or pharmacokinetic enhancement. Compounds that are substrates to CYP 450 are most likely to be metabolized, and this can result into either their deactivation or creation of more active metabolites [22].

With the exception of compounds 25 and 37, the rest of the compounds had low clearance rates implying that they are more likely to accumulate and stay longer in than body. Clearance affects both the half-life and bioavailability of drugs, thereby directly influencing the dose and dosing frequency of a drug. As much as low clearance is advantageous as it leads to less frequent dosing, it might enhance the toxicity of the compound if the toxicity is concentration-dependent [43]. Although all the compounds were liable to cause skin sensitization, they demonstrated acceptable safety profiles on all other toxicity parameters except compound 43, which showed mutagenic potential. In conclusion, the ADMET results imply that the top docked compounds possess variable promising pharmacokinetic properties with minimum toxicity. Hence, the most active compounds in silico could be isolated and considered for optimization and further validation.

4.6. Limitation of the Study. The NIST library could have lacked some chemical compounds that were present in the extracts and therefore could not be identified. It is also possible that some less volatile and thermally labile compounds were not derivatized and hence could not be detected by the GC-MS system.

5. Conclusion

There are phytochemicals in A. coriaria with potential antimycobacterial activity and acceptable cytotoxicity, which can be further explored and optimized for the development of new antitubercular drugs.

Data Availability

The raw data supporting the conclusions of this study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Scientific and Ethics Research Unit, Kenya Medical Research Institute (KEMRI/SERU/CTMDR/CSCP085/4067). Maximum care was taken during harvesting medicinal plants to ensure the sustainability of the plants. The antimycobacterial assays were carried out at the biosafety level-three (BSL 3) laboratory under the supervision of trained personnel to protect the researchers against possible infection. Use of personal protective equipment and compliance to standard operating procedures during the experiments were adhered to.

Consent

Not applicable.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors’ Contributions

SBO conceptualized the study and applied for funding under the supervision of AK, EK, and IK. SBO conducted the laboratory experiments, data curation, and analysis with technical support from RC, ROO, and MA. SBO, ROO, and MA drafted the manuscript, which was reviewed by the other authors. All authors read and approved the final manuscript.

Acknowledgments

The authors are grateful to the World Bank and the Inter-University Council of East Africa (IUCEA) for the PhD scholarship awarded to Samuel Baker Obakiro through the Africa Centre of Excellence II in Phytochemicals, Textile and Renewable Energy (ACE II PTRE) at Moi University, Kenya. The authors sincerely appreciated the community of Kisumu and Siaya Counties of Western Kenya for sharing their indigenous knowledge about the use of this medicinal plant. David Mutende, Evarest Natugonza, and Peter Kizito of Directorate of Government Analytical Laboratories, Wandegeya, Kampala (Uganda), are thanked for their technical contribution rendered during the GC-MS analysis. Mr. Nicholas Adipo at CTMDR, KEMRI, for technical support in the cytotoxicity assay. Lastly, thanks to Vicent Kamya, Mark Peter Odero, and Timothy Omara for the technical support rendered throughout the execution of the research project. This research was supported by the International Foundation for Science (IFS), Stockholm, Sweden, and the Organization for the Prohibition of Chemical Weapons (OPCW) through a grant to Samuel Baker Obakiro (Grant no. I-1-1-F-6451-1) and also by the Africa Centre of Excellence II in...
Phytochemicals, Textile and Renewable Energy (ACE II PTRE), Moi University, Kenya (Credit no. 5798-KE).

References

[1] S. Y. Rodriguez-Takeuchi, M. E. Renjifo, and F. J. Medina, "Extrapulmonary tuberculosis: pathophysiology and imaging findings," Radiographics, vol. 39, no. 7, pp. 2023–2037, 2019.

[2] World Health Organization, Global Tuberculosis Report 2021, World Health Organization, Geneva, Switzerland, 2021, https://www.who.int/tb-reports/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.

[3] D. Falzon, H. J. Schüinemann, E. Harauz et al., "World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update," European Respiratory Journal, vol. 49, no. 3, Article ID 1602308, 2017.

[4] A. Godebo, H. Abiy, and A. Toma, "Recent advances in the development of anti-tuberculosis drugs acting on multidrug-resistant strains: a review," International Journal of Research and Pharmaceutical Bioscience, vol. 2, pp. 1–18, 2015.

[5] L. D’Ambrosio, R. Centis, G. Soitgi, E. Pontali, A. Spanevelo, and G. B. Migliori, "New anti-tuberculosis drugs and regimens: 2015 update," ERJ Open Research, vol. 1, no. 1, p. 00010, 2015.

[6] A. K. Shakya, "Medicinal plants: future source of new drugs," International Journal of Herbal Medicine, vol. 4, no. 4, pp. 59–64, 2020.

[7] L. Bunalema, S. Obakiro, J. R. S. Tabuti, and P. Waako, "Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda," Journal of Ethnopharmacology, vol. 151, no. 2, pp. 999–1004, 2014.

[8] P. Tugume, E. K. Kakudidi, M. Buyinza et al., "Ethnobotanical survey of medicinal plant species used by communities around Mabira Central Forest Reserve, Uganda," Journal of Ethnobiology and Ethnomedicine, vol. 12, no. 1, p. 5, 2016.

[9] N. Shiracko, B. O. Owuor, M. M. Gakuzibi, and W. Wanzala, "A survey of ethnobotany of the AbaWanga people in Kakamega county, Western province of Kenya," Indian Journal of Traditional Knowledge, vol. 15, pp. 93–102, 2016.

[10] J. A. Orodho, C. Kirumuhuya, J. N. Otieno, J. J. Magadula, and P. Okemo, "Local management of tuberculosis by traditional medicine practitioners in lake Victoria region," The Open Complementary Medicine Journal, vol. 3, no. 1, pp. 1–9, 2011.

[11] T. Omara, A. K. Kiprop, and V. J. Kgosgi, "Albizia coriaria Welw ex Oliver: a review of its ethnobotany, phytochemistry and ethnopharmacology," Advances in Traditional Medicine, 2021.

[12] R. Byamukama, G. Barbara, J. Namukobe, M. Heydenreich, and B. Kiremire, "Bioactive compounds in the stem bark of Albizia coriaria (Welw. ex Oliver)," International Journal of Brain and Cognitive Sciences, vol. 9, no. 2, pp. 1013–1024, 2015.

[13] T. Omara, A. K. Kiprop, and V. J. Kgosgi, "Intraspecific variation of phytochemicals, antioxidant, and antibacterial activities of different solvent extracts of Albizia coriaria leaves from some agroecological zones of Uganda," Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 2335454, 14 pages, 2021.

[14] T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983.
[30] M. Ayaz, F. Ullah, A. Sadiq et al., "Synergistic interactions of phytochemicals with antimicrobial agents: potential strategy to counteract drug resistance," Chemico-Biological Interactions, vol. 308, pp. 294–303, 2019.

[31] M. A. Jyoti, K.-W. Nam, W. S. Jang et al., "Antimycobacterial activity of methanolic plant extract of Artemisia capillaris containing ursolic acid and hydroquinone against Mycobacterium tuberculosis," Journal of Infection and Chemotherapy, vol. 22, no. 4, pp. 200–208, 2016.

[32] C. Ma, N. He, Y. Zhao, D. Xia, J. Wei, and W. Kang, "Antimicrobial mechanism of hydroquinone," Applied Biochemistry and Biotechnology, vol. 189, no. 4, pp. 1291–1303, 2019.

[33] N. U. Olivia, C. G. Umeh, and M. O. Ogugor, "Phytochemical profiling and GC-MS analysis of aqueous methanol fraction of Hibiscus asper leaves," Future Journal of Pharmaceutical Sciences, vol. 7, no. 59, pp. 1–5, 2021.

[34] M. T. Shaaban, M. F. Ghaly, and S. M. Fahmi, "Antibacterial activities of hexadecanoic acid methyl ester and green-synthesized silver nanoparticles against multidrug-resistant bacteria," Journal of Basic Microbiology, vol. 61, no. 6, pp. 557–568, 2021.

[35] E. Khatiwora, V. B. Adsul, M. Kulkarni, N. R. Deshpande, and R. V. Kashalkar, "Antibacterial activity of Dibutyl Phthalate: a secondary metabolite isolated from Ipomoea carnea stem," Journal of Pharmaceutical Research, vol. 5, pp. 101–104, 2018.

[36] P. K. Deb, N. A. Al-Shar’i, K. N. Venugopala, M. Pillay, and P. Borah, "In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis," Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 36, no. 1, pp. 869–884, 2021.

[37] P. Lu, H. Lill, and D. Bald, "ATP synthase in mycobacteria: special features and implications for a function as drug target," Biochimica et Biophysica Acta (BBA)—Bioenergetics, vol. 1837, no. 7, pp. 1208–1218, 2014.

[38] F. Appetecchia, S. Consalvi, C. Scarpecci, M. Biava, and G. Pocchi, "SAR analysis of small molecules interfering with energy-metabolism in Mycobacterium tuberculosis," Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 13, no. 9, p. 227, 2020.

[39] L. Novoa-Aponte and Y. S. O. Carlos, "Mycobacterium tuberculosis P-type ATPases: possible targets for drug or vaccine development," BioMed Research International, vol. 2014, Article ID 296986, 9 pages, 2014.

[40] S. S. Çınaro˘glu and T. Emel, "Insights into an alternative benzofuran binding mode and novel scaffolds of polyketide synthase 13 inhibitors," Journal of Molecular Modeling, vol. 25, no. 5, p. 130, 2019.

[41] A. Krüler, G. M. Vinicius, and W. Carsten, "ADME profiling in drug discovery and a new path paved on silica," in Drug Discovery and Development-New Advances, pp. 1–30, Intechopen, London, UK, 2019.